Peptides for Weight Loss

Weight Loss Peptide Therapy Overview

Peptide therapy has become one of the most effective medical approaches to sustainable weight loss. GLP-1 receptor agonists like Semaglutide and Tirzepatide have demonstrated 15–20% body weight reduction in clinical trials, while compounded peptides like AOD-9604 target fat metabolism directly. With RFK Jr. moving to reclassify several peptides for legal compounding in 2026, access to these therapies is expanding rapidly.

• Appetite suppression and reduced cravings
• Targeted fat metabolism without muscle loss
• Improved insulin sensitivity and blood sugar control
• Sustainable long-term weight management
• Potential cardiovascular benefits (GLP-1s)

How Weight Loss Peptides Work

Weight loss peptides work through several distinct biological mechanisms. GLP-1 agonists (semaglutide, tirzepatide) mimic the incretin hormone GLP-1, which signals the brain's appetite centers to reduce hunger, slows gastric emptying so food stays in the stomach longer, and improves insulin sensitivity. Tirzepatide adds a second mechanism via GIP receptor activation, which enhances fat metabolism. AOD-9604 is a fragment of human growth hormone (amino acids 177–191) that stimulates lipolysis — the breakdown of stored fat — without the blood sugar or growth effects of full HGH. CJC-1295 + Ipamorelin stimulate natural growth hormone production, which shifts body composition toward lean mass over fat storage. Most patients start with a low dose and titrate up over 12–16 weeks to minimize GI side effects.

Peptides Used for Weight Loss

Who Is Weight Loss Peptide Therapy For?

Weight loss peptide therapy is typically prescribed for adults with a BMI ≥30 (obese) or BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia). It's also used for patients who have failed to achieve meaningful results with diet and exercise alone, or who have regained weight after previous interventions. GLP-1 therapy is not recommended for patients with a history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, or who are pregnant or breastfeeding.

A typical weight loss peptide protocol begins with a medical evaluation including baseline labs (HbA1c, lipid panel, thyroid, CMP). Semaglutide starts at 0.25mg/week and titrates to 2.4mg over 16 weeks. Tirzepatide follows a similar escalation from 2.5mg to 15mg. Most providers include monthly check-ins, lab monitoring at 12 weeks, and dietary guidance — particularly around protein intake (25–30g per meal) to preserve lean muscle mass during rapid weight loss. Compounded formulations are available as subcutaneous injections, sublingual drops, or oral tablets depending on the provider.

Weight Loss Peptide News

News aggregated via Google News. Inclusion does not imply endorsement.

Weight Loss Guides & Resources

Weight Loss Peptide FAQs